title: Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
abstract: Capillary leak syndrome (CLS) commonly occurs in the intensive care setting. CLS is seen in conditions such as septic shock or may result from conditions such as multitrauma and pancreatitis, which result in the systemic inflammatory response syndrome (SIRS). We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously. We discuss how these patients management differs from other intensive care unit patients with CLS and how it is important to diagnose this condition early in haematological oncology cases.
authors.affiliation: Department of Intensive Care Medicine, Royal Berkshire NHS Trust, Reading, Hampshire, UK. rechner@doctors.org.uk
authors.forename: Ian
authors.initials: I
authors.lastname: Rechner
authors.forename: Finella
authors.initials: F
authors.lastname: Brito-Babapulle
authors.forename: Jonathan
authors.initials: J
authors.lastname: Fielden
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D019559:Capillary Leak Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D003131:Combined Modality Therapy; D003422:Critical Care; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004417:Dyspnea / Q000209:etiology; D004487:Edema / Q000209:etiology / Q000503:physiopathology; D019115:Fasciitis, Necrotizing / Q000209:etiology; D017809:Fatal Outcome; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D008954:Models, Biological; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D013792:Thalidomide / Q000627:therapeutic use; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008775:Methylprednisolone; D006918:Hydroxyurea